Side Effects of Methotrexate for Psoriasis Therapy
Downloads
Background: Psoriasis is a chronic and relapsing inflammatory disease of the skin, characterized by the presence of well-defined erythematous plaque covered by silvery-white scales. Methotrexate is a folic acid antimetabolic for psoriasis therapy and given systemically so unexpected effects can occur. Purpose: To evaluate the side effects of methotrexate as therapy in psoriasis. Methods: The descriptive research based on the medical record of psoriasis patients who were treated for hospitalization on at Kemuning I and II ward Dr. Soetomo General Academic Hospital Surabaya during the period January 2017 – December 2018. The sampling method used was total sampling. Result: Twenty two psoriasis patients receiving methotrexate therapy with the dose of methotrexate is 10-15 mg once weekly, there were 4.5% low erythrocyte level, 27.3% high leukocyte level, 13.6% high thrombocyte level, 18.2% high SGOT level, 22.8% high SGPT level, 18% nausea, 9.1% vomiting, 4.6% headache, and 4.6% shortness of breath. Conclusion: Methotrexate for psoriasis therapy may cause several side effects even not the severe ones, therefore careful dosing and side effect monitoring are necessary.
James, William D, Berger, Timothy G, Elston, Dirk M. Andrews' Diseases of the Skin: Clinical Dermatology. 11th ed. London: Saunders /Elsavier. 2011. p. 190-6.
Gudjonsson JE, Elder JT. Psoriasiform Disorders. In: Kang S, Amagai M, Bruckner AL, Enk AH, Margolis DJ, McMichael AJ et al, editors. Fitzpatrick's dermatology in general medicine. 9th ed. New York: McGraw-Hill. 2019. p. 413-56.
World Health Organization. Global report on psoriasis. Switzerland. 2016.
Gayatri L and Ervianti E. Studi retrospektif: psoriasis pustulosa generalisata, Periodical of Dermatology and Venereology 2004; 26(1): 1-8.
Moningka A, Kandou RT, Niode NJ. Profil Psoriasis di Poliklinik Kulit dan Kelamin RSUP Prof. Dr. R. D. Kandou Manado Periode Januari-Desember 2012. Jurnal e-Clinic (eCI) 2015; 3(2): 646-50.
Kim W, Jerome D, Yeung J. Diagnosis and management of psoriasis. Canadian Family Physician 2017; 63(4): 278–85.
Haider S, Wahid Z, Saher NU, Riaz F. Efficacy of methotrexate in patients with plaque type psoriasis. Pakistan Journal of Medical Sciences 2014; 30(5): 1050-3.
Warren RB, Mrowietz U, Kiedrowski RV, Niesmann J, Wilsmann D, Ghoreschi K, et al. An intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe plaque-type psoriasis (METOP): a 52 week, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017; 389 (10068): 528-37.
Nafiraldi, Sulistia Gain, 2016, Antikanker, Farmakologi dan Terapi. 6th ed. Jakarta: Balai Penerbit FK UI. 2016. p. 737-62.
Operacz MC, Przytocka AS, 2014. The possibilities and principles of methotrexate treatment of psoriasis – the updated knowledge. Advances in Dermatology and Allergology 2014; 31(6): 392-400.
Busard C, Menting S, Bezooijen S, Reek J, Hutten B, Prens E, et al. Optimizing adalimumab treatment in psoriasis with concomitant methotrexate (OPTIMAP): study protocol for a pragmatic, single-blinded, investigator-initiated randomized controlled trial. Trials 2017; 18(1):52-8.
Heller MM, Lee ES, Koo JYM. Stress as an influencing factor in psoriasis. Skin Therapy Letter 2011; 16(5): 1-4.
Weidmann A, Foulkes AC, Kirkham N, Reynolds NJ. Methotrexate toxicity during treatment of chronic plaque psoriasis: a case report and review of the literature. Dermatol Ther (Heidelb) 2014; 4(2): 145-56.
Trevor AJ, Katzung BG, Masters SB, Hall MK. Katzung & Trevors's Pharmacology Examination & Board Review. New York: McGraw-Hill Companies. 2012. p. 469-3.
Pathirana D, Ormerod AD, Saiag P, Smith C, Spuls PI, Nast A, Barker J, et al. European S3-Guidelines on the systemic treatment of psoriasis vulgaris. Journal of the European Academy of Dermatology and Venereology 2009; 24(1): 117-8.
Bezabeh S, Mackey AC, Kluetz P, Jappar D, Korvick J. Accumulating evidence for a drug-drug interaction between methotrexate and proton pump inhibitors. The Oncologis 2012; 17(4): 550-4.
Wilmana PF, Sulistia G. Farmakologi dan terapi. Analgesik-antipiretik analgesik anti inflamasi non steroid dan obat gangguan sendi lainnya. 6th ed. Jakarta: Balai penerbit FK UI. 2016. p. 234-51.
National Institutes of Health. Overview Methotrexate. US. 2019.
Pattabang, Iola, & Wangko, Sunny. Peran sel stelata hepatik pada sirosis hepatis. Jurnal Biomedik 2009; 1(1): 23-8.
Martodiharjo S. Pedoman Diagnosis dan Terapi Bag/SMF Ilmu Penyakit Kulit dan Kelamin. 3rd ed. Surabaya: FK Unair. 2005. p. 92-96.
- Copyright of the article is transferred to the journal, by the knowledge of the author, whilst the moral right of the publication belongs to the author.
- The legal formal aspect of journal publication accessibility refers to Creative Commons Atribusi-Non Commercial-Share alike (CC BY-NC-SA), (https://creativecommons.org/licenses/by-nc-sa/4.0/)
- The articles published in the journal are open access and can be used for non-commercial purposes. Other than the aims mentioned above, the editorial board is not responsible for copyright violation
The manuscript authentic and copyright statement submission can be downloaded ON THIS FORM.
